Tag: sweet treat

The effects of Ozempic on grocery spending are obvious; the Harvard Business Review found GLP-1 households are spending up to 8 percent less on food. The restaurant industry is suffering, too. Food and Wine warns that the Ozempic effect is “rewriting the rules of dining out.” But the food and dining categories are just the first victims of Ozempic.

Twelve percent of the U.S. population has taken GLP-1s at one time or another, with the number rising to 20 percent of women 50-64.  In September, a pill form was introduced, which will undoubtedly increase adoption.

Science is finding that in addition to curbing food cravings, addictions to opioids, alcohol, and nicotine may be treatable with these compounds.

That’s good news for human health. What isn’t getting nearly enough attention, though, is what happens more broadly—beyond food, smoking, substance abuse—when those hormones are suppressed?

Disaster.

The “Impulse Economy” is under siege

Marketers have spent decades getting exquisitely good at creating and monetizing tiny bursts of desire. They are black belts in provoking dopamine release, whether consumers are clicking or scrolling, or getting triggered at the checkout by the cornucopia of impulse purchases. Or being seduced by in-game sports betting.

This emotional manipulation is what powers the consumer economy—which makes up almost 68 percent of U.S. GDP.

But that emotional need is being threatened by the current wave of GLP-1 weight-loss drugs.

Researchers are now noting that, in addition to curbing food, alcohol, and drug cravings, GLP-1 drugs also appear to broadly target the brain’s dopamine reward system, which creates anticipation and the impulse to go after something—or spend money on something.

This can be a punch in the gut to brands. While many discretionary consumer categories are likely to be threatened, it is the most dopamine-driven sectors that will be at heightened risk. You know who they are. Businesses like Fan Duel, Starbucks, the temptations at Costco, the beauty haul at Sephora—these are all powered by dopamine cravings.

So too is the world of direct-to-consumer brands that are successfully turning thumb-stopping into immediate purchase.

A quick look at some basic brain science explains everything.

The billions that are being spent in the non-essential “impulse economy” are the beneficiaries of System One, the so-called fast brain, our more instinctive, quick-turn mechanism.

When System One is blunted, System Two—the slow brain, the more thoughtful and considered processing operation—takes over.  

Here are some quotes from Reddit that capture the GLP-1 effect. There are many others, and they all should be unsettling to the dopamine harvesters out there:

“I found that it actually stopped my shopping impulses, doom scrolling, and any of the other unwanted dopamine-seeking activities,” wrote one user.

From another user: “Came here to mention how much less shopping I’ve been doing! I still go to websites and look at stuff, even add some to my cart, but then I just… don’t feel the need to check out. Very unexpected, but it’s definitely saving me money!”

As GLP-1 drugs are being researched for more and more conditions—like cognitive decline, neurodegenerative diseases, cardiovascular disease, and others—millions more will have this Reddit reaction.

Master the slow brain

You can’t reignite the craving circuits GLP-1s dampen. Biology now outranks branding on that axis. But marketers can tap the pathways GLP-1s don’t blunt. 

Here are five areas where businesses can still succeed in an Ozempic-ruled world.

Identity still matters. People buy to express who they are—or who they want to be. That circuit is intact.

Ritual still works. GLP-1 drugs weaken impulses, not routine. Daily and weekly anchors can replace sugar-rush consumption.

Status endures. Social identity and signaling rely on different neural systems than craving.

Sensory experience is still craveable. Texture, aroma, temperature, sound—sensory design taps pathways outside the dopamine loop.

Goals and completion are still deeply satisfying. Motivation tied to progress, tracking, achievement, and self-improvement is strong and unaltered.

In short, brands relying on impulsivity will struggle with GLP-1. Brands that reroute desire into underlying psychological truths can thrive.

A five-point plan for marketing to muted desire

Build on the slow brain hacks described above with these techniques.

Don’t run from logic. Marketers have spent decades focusing on emotional versus rational drivers.  GLP-1 allows space for the logical, so make sure your marketing narrative responds accordingly.  With craving dialed down, the rational brain gets a bigger share of the vote.

Simplify choice. A cooler dopamine baseline has less tolerance for clutter and SKU overload. This also has graphic and aesthetic applications—give the brain a visually calm resting place.  

Design rituals, not jolts. The comfort of habit can replace the reward loop of impulse and become a dependable driver of repeat behavior. Higher levels of dopamine drive consumers to seek novelty, which leads to brand switching. Lower levels can actually make brands stickier and generate loyalty.

Don’t be pushy. The fast brain is wired for quick decisions; it doesn’t mind being pushed and rushed. FOMO works with System One. The slow brain likes to think things over, to mull. GLP-1 consumers will appreciate a less in-your-face selling ecosystem.

Invest in confidence. In a new world where immediacy is replaced by contemplation, make sure your brand delivers on that extended marketing moment. That could mean using third-party experts to add reinforcement and credibility. Real authority versus superficial influencer hype. Extending your guarantee to de-risk the purchase is also slow brain candy.

Neurochemical quieting may be the biggest unmodeled demand shock in decades.

What happens when the American shopper becomes less temptable? When the internal amplifier that turns tiny stimuli into potent urges gets turned to a lower setting?

We’re about to find out.

The final deadline for the 2026 Inc. Regionals Awards is Friday, December 12, at 11:59 p.m. PT. Apply now.